Skip to content

Home Telemonitoring System for Diabetic Patients: a randomised controlled crossover study.

Home Telemonitoring System for Diabetic Patients: a randomised controlled crossover study. - Home Telemonitoring System for Diabeteic Patients

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000011219
Enrollment
200
Registered
2013-07-18
Start date
2011-03-23
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

diabetes mellitus

Interventions

Intervention period to non-intervention period, 1)Intervention period(one year): Home telemonitoring system using multi-functional mobile phone for a year 1)Every day:records of meals(photos), bo

Sponsors

Kanazawa University Hospital,Department of Endocrinology and Metabolism
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1) Patients with diabetes or impaired glucose tolerance 2) HbA1C 5.2~7.0% (JDS) 3)Patients whose content is obtained in written form

Exclusion criteria

Exclusion criteria: 1) Patients with malignant hypertension or secondary hypertension 2) Diabetic patients requiring insulin therapy 3) Pregnant and probably pregnant patients 4) patients with abnormal serum creatinin value 5) Patients with severe hepatic dysfunction 6) Patients who had myocardial infarction or apoplexy within 3 months before the satrt of the study or who are treated. 7) Patients with severe allergy or with steroid therapy 8) Patients with pancreatitis or pasthistory of pancreatitis 9) Patients with malignacy 10) Other patients judged as being inappropriate for the subjects of the study by investigators

Design outcomes

Primary

MeasureTime frame
Following items at every 3 months 1 changes in plasma glucose level and HbA1C 2 Changes in urine alubumin excretion 3 Changes in lipid levels 4 Changes in blood pressure 5 Changes in body weight and body mass index(BMI) 6 Occurrence of diabetic complication 7 Newly required medicine for diabetes, blood pressure, or dyslipidemia

Countries

Japan

Contacts

Public ContactTakashi Yoneda

Kanazawa University Kanazawa University Hospital

endocrin@med.kanazawa-u.ac.jp+81762652252

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026